Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3817658 | 0.98 | ELANE (0.45) | ELANENOS1KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4777090 | 0.98 | ELANE (0.45) | ELANENOS1KDM4EALDH1A1HPGD | |
| SCHEMBL20745704 | 0.84 | NOS1 (0.45) | ELANENOS1FBP1 | |
| SCHEMBL4566478 | 0.84 | NOS1 (0.46) | ELANENOS1ALDH1A1TSHR | |
| SCHEMBL29082805 | 0.82 | ELANE (0.37) | ELANENOS1KDM4EALDH1A1HPGD | |
| SCHEMBL23674662 | 0.81 | NLRP3 (0.39) | ELANENOS1KDM4EALDH1A1HPGD | |
| SCHEMBL4669624 | 0.80 | ELANE (0.41) | ELANENOS1KDM4EALDH1A1HPGD | |
| SCHEMBL23674663 | 0.80 | NOS1 (0.38) | ELANENOS1KDM4EALDH1A1HPGD | |
| SCHEMBL6220651 | 0.79 | — | — | |
| SCHEMBL15500843 | 0.75 | L3MBTL1 (0.48) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973767-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | Dupont Pharmaceuticals Company (US) | 2000-01-26 | — | — | EP | claimed |
| US-5985867-A | TREATING HIV INFECTION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-11-16 | — | — | US | claimed |
| WO-1998043969-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
| EP-0293220-B1 | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing | ORTHO PHARMA CORP (US) | 1994-08-31 | — | — | EP | claimed |
| EP-0293220-A2 | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-11-30 | — | — | EP | claimed |
| JP-6041455-A | — | — | None | — | — | JP | disclosed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| CN-119384413-A | Anilino-pyrazole derivatives, compositions and methods thereof | 昂胜医药有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113330000-B | 3-Carbonylamino-5-cyclopentyl-1 FI-pyrrole compounds having inhibitory activity on CDK2 | 辉瑞公司 | 2024-12-24 | — | — | CN | disclosed |
| CN-118290357-A | Heterocyclic compounds useful in the treatment of disease | 艾匹根生物技术有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118162074-A | A high-efficient cyclization micro-reaction unit for pyrazolidine ethyl formate | 江苏优普生物化学科技股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-111770923-B | Heterocyclic compound and harmful arthropod control agent containing same | 住友化学株式会社 | 2024-04-09 | — | — | CN | disclosed |
| WO-2007062996-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AND AZA-SUBSTITUTED INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| CN-1823074-A | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH CORP (US) | 2006-08-23 | — | — | CN | disclosed |
| US-6712890-B2 | WATER SOLUBLE DYES HAVING GOOD LIGHTFASTNESS AND OPTICAL DENSITY | AVECIA LIMITED (GB) | 2004-03-30 | — | — | US | disclosed |
| US-20020130937-A1 | Compositions | AVECIA LIMITED | 2002-09-19 | — | — | US | disclosed |
| US-6306911-B1 | ENZYME INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-10-23 | — | — | US | disclosed |
| US-5985867-A | TREATING HIV INFECTION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0667868-A1 | NEW CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-08-23 | — | — | EP | disclosed |
| JP-H0641455-A | FIBER REACTIVE MONOAZO YELLOW DYE | HOECHST CELANESE CORP | 1994-02-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ELANE 153/4885NOS1 2540/4885KDM4E 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.